Ensign’s Earnings Call Highlights Record Growth and Strength
The Ensign ((ENSG)) has held its Q4 earnings call. Read on for the main highlights of the call.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The Ensign Co. struck an upbeat tone on its latest earnings call, highlighting record quarterly and full‑year results, accelerating growth and strengthening operations. Management acknowledged pockets of regulatory and labor risk, as well as rising deal costs, but argued that robust cash flow, low leverage and improving quality metrics leave the company well positioned for further expansion.
Record Financial Performance in 2025 and Q4
Full‑year 2025 revenue rose 18.7% to $5.1 billion, with GAAP diluted EPS up 14.1% to $5.84 and adjusted EPS up 19.5% to $6.57. GAAP net income climbed 15.4% to $344 million, while adjusted net income grew 20.6% to $386.6 million, underscoring strong operational leverage.
Q4 was even stronger, with revenue up 20.2% to $1.4 billion and GAAP diluted EPS up 18.4% to $1.61. Adjusted EPS increased 22.1% to $1.82 and adjusted net income rose 23.2% to $107.8 million, showing momentum heading into the new year despite sector headwinds.
Multi‑Year Growth Trajectory Remains Intact
Over the last five years, Ensign’s total adjusted revenue has increased by $2.7 billion, a 111% jump that translates into a 16% compound annual growth rate. During the same period, diluted adjusted EPS increased by $3.44, also reflecting a 16% CAGR and steady margin expansion.
Adjusted net income has risen 121% over five years, implying a 17% CAGR and demonstrating the scalability of the company’s operating model. Management framed this track record as evidence that its decentralized local‑leader strategy continues to deliver consistent, durable growth.
Clinical Quality Outperformance Fuels Referrals
Same‑store Ensign operations outperformed peers by 24% at the state level and 33% at the county level in recent CMS survey data. The portfolio also enjoys a 19% advantage in the share of 4‑ and 5‑star buildings versus peers, supporting higher acuity and better payer mix.
On national 5‑star quality measures, same‑store operations performed 22% better than the average and 17% above state benchmarks. Management said these quality gains are translating into stronger referral networks, higher skilled mix and more attractive case complexity.
Occupancy and Payer Mix Hit New Highs
Ensign reported all‑time highs in occupancy, with same‑store facilities at 83.8% and transitioning buildings at 84.9% in the quarter. Skilled nursing days grew 8.5% in same‑store assets and 10% in transitioning operations year over year, confirming healthier demand.
Same‑store Medicare revenue climbed 15.7% with Medicare days up 11% year over year, while managed care revenue rose 8.9% in same‑store and 15% in transitioning operations. Management emphasized that a richer payer and acuity mix has been a key driver of revenue and earnings growth.
Active M&A and Capacity Expansion
Since the start of 2024, Ensign has sourced, underwritten, closed or transitioned 82 new operations, maintaining its reputation as an aggressive consolidator. In the latest quarter alone, it added 17 operations, including 12 real estate assets and 1,371 skilled nursing beds across seven states.
Recently completed strategic deals, including a notable portfolio in Utah, are reportedly performing ahead of underwritten expectations. Management stressed that a disciplined approach to underwriting and integration remains central to its expansion strategy.
Local Market Standouts Demonstrate Model
At South Bay Post Acute, EBIT before tax surged 127% year over year, as occupancy ticked up from 96% to 97% and skilled revenue mix increased 25%. Medicare days jumped 86% and managed care revenue grew 22%, illustrating how local teams can lift both volume and mix.
Shoreline Health delivered an 11% year‑over‑year revenue increase in Q4 and roughly 33% EBIT growth. Medicare days increased 24%, managed care more than doubled, and skilled revenue mix reached 70%, highlighting the potential embedded in underperforming assets.
Balance Sheet Strength and Ample Liquidity
The balance sheet remains a key support for Ensign’s growth agenda, with $504 million in cash and cash equivalents and $564 million in operating cash flow. The company also has more than $590 million available on its credit line, giving it over $1 billion in total liquidity.
Lease‑adjusted net debt to EBITDA hit a record low of 1.77 times even after more than $500 million of investments in 2025. Ensign owns 160 real estate assets, 136 of them debt‑free, which provides strategic flexibility and downside protection.
Real Estate Platform Adds Diversified Income
Standard Bearer, Ensign’s real estate arm, generated quarterly rental revenue of $34.5 million, including $29.3 million from Ensign affiliates. Funds from operations reached $20.4 million, supported by EBITDAR to rent coverage of 2.6 times across the portfolio.
Standard Bearer now owns 154 properties, with 120 leased to Ensign affiliates and 35 to third parties. Management highlighted this platform as a complementary source of cash flow and a strategic vehicle for capturing long‑term real estate upside.
Consistent Dividend Growth
Ensign increased its dividend for the 23rd consecutive year, underscoring confidence in its cash generation. The company paid a quarterly cash dividend of $0.065 per common share, maintaining a conservative payout while prioritizing reinvestment and acquisitions.
Executives framed the dividend track record as part of a broader capital allocation discipline. They stressed that returns to shareholders will continue to be balanced against funding growth and maintaining a strong balance sheet.
Deal Environment and Acquisition Costs
Management noted that M&A markets have become more seller‑friendly, with rising valuations requiring heightened selectivity. Newer, higher‑quality assets may command pricing premiums and some transactions now involve longer operational ramps before reaching target returns.
Older facilities can demand heavy capital expenditures to modernize, raising all‑in acquisition costs and extending payback periods. Ensign said its decentralized model and real estate expertise help it navigate these dynamics but acknowledged the need for disciplined underwriting.
Occupancy Upside Still Ahead
Even with record same‑store occupancy at roughly 83.8%, management argued there is substantial room for organic growth. Many acquired or recently transitioned operations remain well below the occupancy levels seen at mature campuses, providing a multi‑year improvement runway.
Shoreline Health, for example, has posted strong mix and earnings gains but still operates below 74% occupancy. Executives view these under‑levered assets as key to driving future growth without relying solely on external acquisitions.
Construction and Replacement Challenges
New construction and replacement projects were described as both strategically important and capital intensive. Building or replacing facilities requires significant upfront investment, long timelines and complex licensing processes, which can delay returns.
Management noted that replacement projects can sometimes shorten the payback period compared with pure greenfield builds. Even so, they emphasized careful project selection and budgeting to avoid overextending in a costly development cycle.
Regulatory and Reimbursement Watchpoints
Executives flagged ongoing uncertainties around reimbursement systems, including potential changes in Medicare value‑based purchasing and infection‑related metrics. Delays or revisions in state budgets can also affect revenue visibility and timing for certain markets.
Seasonality in occupancy and skilled mix may further influence quarterly results and reimbursement trends. Management stressed its track record of navigating policy shifts but cautioned that regulatory variability remains a key external risk factor.
Labor and Operational Risks Remain
The company reported improvements in staff turnover, lower reliance on agency labor and a 33% reduction in director of nursing turnover. These gains have helped support margins and operational stability across the portfolio.
However, leadership acknowledged that the broader labor market and seasonal swings can still pressure overtime and agency usage. Continued investment in recruiting, training and leadership development is seen as essential to sustaining recent progress.
Executing on Higher‑Acuity Programs
Ensign is leaning into higher‑acuity offerings such as behavioral health, bariatric care and TPN‑capable services to enhance mix and margins. These programs can deepen relationships with hospitals and payers while raising the clinical profile of its facilities.
At the same time, management conceded that such initiatives carry execution risk because they require specialized training, equipment and partnerships. Some acquisitions may face steeper learning curves as they build these capabilities, potentially lengthening the ramp to full performance.
Guidance Signals Continued Double‑Digit Growth
For 2026, Ensign guided to diluted EPS of $7.41 to $7.61 and revenue between $5.77 billion and $5.84 billion. The midpoint implies around 14.3% EPS growth versus 2025 and roughly 36.5% growth versus 2024, excluding stock‑based compensation and certain amortization.
Guidance assumes roughly 60 million diluted shares and a 25% tax rate and reflects expected gains in occupancy, skilled mix and labor efficiency. Management cautioned that the outlook remains sensitive to reimbursement decisions, state budgets, seasonality and the timing of acquisitions.
Ensign’s latest earnings call painted the picture of a company combining strong fundamentals with disciplined growth in a challenging sector. Record results, robust liquidity and a rich pipeline of operational improvements support the bullish tone, even as management stays candid about regulatory, labor and deal‑market risks that investors should continue to monitor.
